In DM-CHD models, Blimp-1 decreases markers of oxidative stress and atherosclerotic plaque formation, thus offering a therapeutic target for diseases associated with chronic inflammation and oxidative damage [10]. This evidence concerns the gene PRDM1 and coronary artery disorder.